AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03327038 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Detailed Questionnaires
Description: Patients will complete a detailed questionnaires at enrollment (i.e. week 1 of enrollment) and also at post-intervention (i.e. week 8 of enrollment). The enrollment questionnaire will query the patients Ulcerative Colitis Disease Activity (MAYO-6) or Crohn's Disease Activity (PRO-2); Quality of Life (SIBDQ); and Patient Satisfaction with Health Care in IBD (CACHE). The post-intervention questionnaire will query the same information as the enrollment questionnaire but will also ask patients to self-report their depression (PHQ-9) and anxiety (GAD-7) symptoms.Quality of Life will be measured using the 10 item Short Inflammatory Bowel Disease Questionnaire (SIBDQ), which has a total score range of 10 to 70, with higher scores indicating better quality of life. Patient Satisfaction with Health Care in IBD will be measured using the 32 item CACHE Questionnaire, which scores from 0 -least satisfaction to 100-highest satisfaction.
Study NCT03327038 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Screening Form
Description: Patients will complete a screening form at routine IBD outpatient visits to Mount Sinai Hospital to self-report their depression and generalized anxiety symptoms. Their depression symptoms will be reported on the 9-item Patient Health Questionnaire (PHQ-9), which has a total score ranging from 0 to 27, with scores of 5, 10, 15 and 20 representing cut points for mild, moderate, moderately severe, and severe depression. Their generalized anxiety symptoms will be reported on the 7-item Generalized Anxiety Disorder Questionnaire (GAD-7), which has a total score ranging from 0 to 21, with scores of 5, 10, and 15 representing cut points for mild, moderate, and severe anxiety. Patients who self-report scores of moderate depression AND/OR moderate anxiety will be eligible to participate in this study.
Study NCT03327038 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Screening Form
Description: Patients will complete a screening form at routine IBD outpatient visits to Mount Sinai Hospital to self-report their depression and generalized anxiety symptoms. Their depression symptoms will be reported on the 9-item Patient Health Questionnaire (PHQ-9), which has a total score ranging from 0 to 27, with scores of 5, 10, 15 and 20 representing cut points for mild, moderate, moderately severe, and severe depression. Their generalized anxiety symptoms will be reported on the 7-item Generalized Anxiety Disorder Questionnaire (GAD-7), which has a total score ranging from 0 to 21, with scores of 5, 10, and 15 representing cut points for mild, moderate, and severe anxiety. Patients who self-report scores of moderate depression AND/OR moderate anxiety will be eligible to participate in this study.
Study NCT01719991 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nurse case management and self-management support
Description: Case management: The intervention will focus on four main components: (1) A thorough evaluation of the patient's needs and resources; (2) Establishing and maintaining a patient-centered, individualized service plan (ISP); (3) Coordination of services among partners; and (4) Self-management support for patients and their families.~Self-management support: A standardized six-week program with interactive weekly group meetings led by two volunteer peer helpers (appointed trainers), who themselves have a chronic disease.
Study NCT00944632 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ZK 245186
Description: Once daily topical non-occlusive application for up to 4 weeks
Study NCT00944632 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (vehicle ointment)
Description: Once daily topical non-occlusive application for up to 4 weeks
Study NCT00672633 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lovaza
Description: Lovaza , 4 grams/day orally for 6 months
Study NCT00672633 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Corn Oil Pill, 4 pills/day orally for 6 months
Study NCT00778791 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metformin HC1 750 mg extended-release tablets
Study NCT01298167 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cyanoacrylate tissue glue versus Fast absorbing gut
Description: All wounds will be closed using a linear, bilayered closure method, where the buried intradermal absorbing suture (5-0, Polysorb) will be placed along the length of the incision, consistent with standard surgical procedure. Only patients with wounds with a length of 3cm or greater will be enrolled. Each wound will be measured, and the length divided in half. Half of the surgical wound will be randomly selected (by coin toss) for epidermal reapproximation with cyanoacrylate, whereas the other half will be repaired with 6-0 fast absorbing gut suture in standard running fashion.
Study NCT05515510 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: FU-APP
Description: FU-APP is a web-based application using the guidelines and oral health recommendations provided by the current German Ratgeber 2020. It provides information related to oral health care for the parents of children between 6 to 72 months of age. An account was made on a certified online web-development platform and an application was developed on it.~This application serves as a practical guide for the parents of children under 6 years of age. It provides all the essential German guidelines related to first dental visits, expected dental findings, practical brushing technique steps, plaque disclosing activity, motivational brushing video, nutritional facts and behavioral habits to be avoided. It is a complete package of essential information and with high quality content that promotes prevention of ECC at an early age.
Study NCT05515510 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Oral health recommendations
Description: Oral health recommendations provided as usual (verbal/oral) according to the current German Ratgeber 2020
Study NCT05515510 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oral health recommendations
Description: Oral health recommendations provided as usual (verbal/oral) according to the current German Ratgeber 2020
Study NCT00553527 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Humeral Stem replacement surgery
Description: Patient will receive humeral stem replacement.
Study NCT02005237 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic Exercise
Description: 3-months exercise program tailored to the individual level of aerobic fitness. Patients will exercise on a bicycle ergometer (2-3 session per week) according to a predefined training plan with increasing duration and intensity
Study NCT01750645 — intervention group
Intervention type: DRUG
Intervention: Intradetrusor Injection of Type-A Botulinum Toxin
Study NCT01750645 — intervention group
Intervention type: OTHER
Intervention: Other interventions analyzed according to protocol
Description: * Placebo~* Different dosage of Type-A Botulinum Toxin injected~* Anticholinergic drugs
Study NCT00520039 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: osteopathic manipulative medicine (OMM)
Description: At each of the first three study visits, all subjects in the osteopathic manipulative medicine (OMM) group will receive OMM using the prescribed protocol.
Study NCT03454451 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CPI-006
Description: Subjects will receive escalating doses of CPI-006 administered intravenously once every 21 days until MTD is reached or until disease progression.
Study NCT03454451 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CPI-006 + ciforadenant
Description: Subjects will receive escalating doses of CPI-006 administered intravenously once every 21 days in combination with CPI-444 orally twice daily until MTD is reached for CPI-006 or until disease progression.
Study NCT03454451 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CPI-006 + pembrolizumab
Description: Subjects will receive escalating doses of CPI-006 in combination with pembrolizumab administered intravenously once every 21 days until MTD is reached for CPI-006 or until disease progression.
Study NCT03454451 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CPI-006
Description: Selected dose of CPI-006 administered intravenously once every 21 days until disease progression.
Study NCT03454451 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CPI-006 + ciforadenant
Description: Selected dose of CPI-006 administered intravenously once every 21 days, in combination with CPI-444 orally twice daily until disease progression.
Study NCT03454451 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CPI-006 + pembrolizumab
Description: Selected dose of CPI-006 in combination with pembrolizumab administered intravenously once every 21 days until disease progression.
Study NCT01210482 — intervention group
Intervention type: DRUG
Intervention: Temsirolimus
Description: The usual adult dosage is temsirolimus 25 mg once weekly, to be administered via gradual intravenous infusion over 30\~60 minutes. The dosage is to be appropriately reduced according to patients' status.
Study NCT04482088 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Occupational Therapy in an Equine Environment
Description: 10 weeks of occupational therapy in an equine environment aimed at improving individual goals related to self-regulation, social communication, and play
Study NCT04482088 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Occupational Therapy in a Clinic (OTC)
Description: 10 weeks of occupational therapy in a clinic aimed at improving individual goals related to self-regulation, social communication, and play
Study NCT02927574 — intervention group
Intervention type: DEVICE
Intervention: DCB
Study NCT02927574 — intervention group
Intervention type: DEVICE
Intervention: POBA
Study NCT03264937 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social-software management
Description: Using Wechat application, a social platform, to manage warfarin therapy in patients with mechanical valve replacement.
Study NCT03455257 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cash Transfer
Description: The heads of households will receive a cash transfer for up to 7 family members in the home every quarter. Head of households will be expected to attend meetings every 4 months at their local community health centers led by Community Health Workers (CHW). Meetings will have 2 components: 1) children under 5 will be measured to identify children at risk of malnutrition and 2) group education sessions. There will also be monthly growth monitoring and education sessions led by CHW for a subgroup of head of households with children identified as risk of malnutrition with rapid referrals to regional tertiary clinics for any children with health problems that cannot be addressed by CHW.
Study NCT03896581 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bimekizumab
Description: Subjects will receive bimekizumab at pre-specified time-points.
Study NCT03896581 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects will receive placebo at pre-specified time-points.
Study NCT02051062 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blood sample collection
Description: One to three 5 mL blood samples will be collected from pediatric participants treated with BAT product ideally 6-24 hours after administration but within a maximum of 32 hours after administration.
Study NCT03862092 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Salivary VZV-DNA PCR
Description: VZV-DNA PCR of saliva samples
Study NCT02338115 — intervention group
Intervention type: DRUG
Intervention: Paclitaxel 80mg/m2 weekly x 12 weeks
Study NCT02002871 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PSO-CT02 device
Description: The PSO-CT02 device is worn on the affected skin area where it irradiates the target Eczema area for 30 minutes with blue light. A contralateral eczema area is left untreated and serves as control.
Study NCT03442231 — intervention group
Intervention type: DEVICE
Intervention: Journey UNI Unicompartmental Knee System
Description: Lateral or medial knee compartment replacement
Study NCT04129294 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NS-089/NCNP-02
Description: NS-089/NCNP-02 for Infusion is packaged as 50 mg/mL with 3 mL per vial. Study dosages will be infused over a 1 hour period at the following dose levels.~\[Part 1\] NS-089/NCNP-02 is administered at dose levels 1 and 3 in Cohort 1 and at dose levels 2 and 4 in Cohort 2.~Dose level 1: 1.62 mg/kg once weekly for 2 weeks; Dose level 2: 10 mg/kg once weekly for 2 weeks; Dose level 3: 40 mg/kg once weekly for 2 weeks; Dose level 4: 80 mg/kg once weekly for 2 weeks \[Part 2\] Based on the results from Part 1, two dosages are selected as study dosages in Part 2. Each selected dose are administered once a week for 24 weeks.
Study NCT00574093 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranibizumab; Verteporfin
Description: Patients will be administered Lucentis™ 0.5 mg on Day 1, at Months 1 and 2, and then as needed at intervals of at least 30 days through Month 11 based on the retreatment criteria algorithm. These patients will also be administered Visudyne® only on Day 3.
Study NCT00528359 — intervention group
Intervention type: DRUG
Intervention: quetiapine or olanzapine or risperidone or aripiprazole
Study NCT03606057 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-64565111
Description: Participants will receive JNJ-64565111, subcutaneously on days 2, 9, 16, and 23.
Study NCT03606057 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moxifloxacin
Description: Participants will receive moxifloxacin capsule on days 1 or 27 in a nested crossover manner.
Study NCT03606057 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: JNJ-64565111-matching Placebo
Description: Participants will receive JNJ-64565111-matching Placebo vehicle solution subcutaneously on days 2, 9, 16, and 23.
Study NCT03606057 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin-matching Placebo
Description: Participants will receive moxifloxacin-matching placebo capsule on days 1 and 27 in treatment group 1 and on day 1 or 27 in treatment group 2.
Study NCT03606057 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moxifloxacin-matching Placebo
Description: Participants will receive moxifloxacin-matching placebo capsule on days 1 and 27 in treatment group 1 and on day 1 or 27 in treatment group 2.
Study NCT01997801 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine infusion
Description: Ketamine will be infused intraoperatively (0.25 mg/kg intravenous bolus following continuous infusion of 100 mcg/kg/hr).
Study NCT01997801 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: NS infusion
Description: Normal saline will be infused intraoperatively.
Study NCT01429441 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ocriplasmin
Description: 0.125 mg single intravitreal injection
Study NCT01429441 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham injection
Description: Sham injection
Study NCT02116725 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Shower gel with zinc
Description: Standard shower gel (Sanex) supplemented with zinc sulfate.
Study NCT02116725 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Plain shower gel
Description: Standard shower gel (Sanex).
Study NCT02116725 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Distilled water
Description: Sterile distilled Water.
Study NCT04554381 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: JL1 antigen
Description: we hypothesis that JL1 can be used as an adjunctive marker for the initial diagnosis and the follow up of Acute Lymphoblastic Leukemia.
Study NCT04418271 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Prehabilitation- new form of care
Description: The participants in the intervention group take part in a shared decision-making (SDM) conference to plan the intervention. The therapeutic content of the prehabilitation is defined individually for each patient in the SDM conference. Prehabilitation will be a structured and individually tailored 3-week program.
Study NCT02330224 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hypertension Management Intervention
Description: The multifaceted intervention consists of three main components:~1. Structured treatment algorithm with fixed dose antihypertensives for high cardiovascular disease risk patients~2. Motivational conversation by nurses and nurse practitioners for high risk patients at baseline~3. Telephone based follow-up for all patients by nurses
Study NCT00806858 — intervention group
Intervention type: DEVICE
Intervention: NovoPen® 4
Description: Insulin administration by means of a NovoPen® 4 pen device
Study NCT00401193 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic acid tablets
Description: 3900 mg/Day
Study NCT00401193 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic acid tablets
Description: 1950 mg/Day
Study NCT00401193 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo tablets
Study NCT04135313 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Description: 2000 mg/m2, bid, per os, days 1-14
Study NCT04135313 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: 2000 mg/m2, bid, per os, days 1-14
Study NCT04135313 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxaliplatin
Description: 130 mg/m2 iv day 1
Study NCT04135313 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: 130 mg/m2 iv day 1
Study NCT04135313 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Description: 825 mg/m2, bid, per os, only on days of radiation (Monday through Friday)
Study NCT04135313 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: 825 mg/m2, bid, per os, only on days of radiation (Monday through Friday)
Study NCT04135313 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiotherapy
Description: Pelvic radiotherapy dose: 44 Gy on regional nodes, 54 Gy on primary tumor in 2 Gy fractions
Study NCT04135313 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Pelvic radiotherapy dose: 44 Gy on regional nodes, 54 Gy on primary tumor in 2 Gy fractions
Study NCT04135313 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Rectal cancer surgery
Description: Laparoscopic or open total mesorectal excision or extralevator abdominoperineal resection
Study NCT04135313 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Rectal cancer surgery
Description: Laparoscopic or open total mesorectal excision or extralevator abdominoperineal resection
Study NCT01206023 — intervention group
Intervention type: OTHER
Intervention: NA-NOSE artificial olfactory system
Description: NA-NOSE is an artificial olfactory system that is based on nanomaterials and connected with machine learning. NA-NOSE can diagnosis diseases or disorders based on volatile biomarkers that are emitted from exhaled breath, blood, or from clinical tissue.
Study NCT03571776 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgery
Description: Laparoscopic ovarian cystectomy
Study NCT03571776 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Sclerotherapy
Description: US-aspiration and alcohol sclerosis
Study NCT03476902 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Therapist assisted mobile intervention
Description: Individuals will receive 4 introductory sessions with a therapist followed by weekly phone calls. Participants will utilize nOCD application to assist with treatment protocol adherence.
Study NCT00171158 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: imatinib mesylate
Study NCT01229319 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cryotherapy alone to Left arm plus cryotherapy + imiquimod to Right arm
Description: Cryotherapy alone to Left arm plus cryotherapy + imiquimod 3.75% daily x 2 weeks on and 2 weeks off and 2 weeks on to Right arm
Study NCT02666820 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Large balloon dilatation
Description: After biliary sphincterotomy was performed with full extension to the full length of transverse fold. A 12, 15, 18 or 20 mm CRE-balloon was passed over guide wire and position across the papilla. The balloon was gradually inflated to the largest size of the bile duct stone and/or the bile duct diameter. When complete stone removal was unsuccessful , crossing over treatment was considered at the discretion of the endoscopists.
Study NCT02666820 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Mechanical lithotripsy
Description: After biliary sphincterotomy was performed with full extension to the full length of transverse fold. A 3x6 cm Trapezoid Rx retrieval stone basket was used to capture the stone and crushing of stones was done when simple stone extraction failed to remove the stone. The stone fragments were then retrieved with a basket and/ or a retrieval balloon. When complete stone removal was unsuccessful , crossing over treatment was considered at the discretion of the endoscopists.
Study NCT01980628 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ibrutinib
Study NCT02731274 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Regular physical activity in Motor memory consolidation
Description: After the intervention, the assessment of the impact of exercise on motor memory consolidation was held in three stages: Training; 1 hour after training and 24 hours after training. For the analysis of the results, descriptive and inferential statistics were used.